ALSO NOTED: Integrated BioPharma looking to spin-off biotech; Eli Lilly to buy Ivy Animal Health; Novagali gains orphan status;

> Integrated BioPharma has retained Merriman Curhan Ford to act as an adviser in the divestiture of its InB:Biotechnologies subsidiary. INBP now expects that the divesture will be structured as a spin-off of Biotech, which will focus on its patented plant-based technology for the production of vaccines, antibodies and therapeutic proteins. Release

> Eli Lilly will buy Ivy Animal Health for an undisclosed sum. Report

> The FDA Has awarded Novagali Pharma orphan drug status for the Cyclosporine A drug Vekacia. Release

And Finally...Pediatricians criticize a discovery system that often neglects children. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.

The series C positions Lava to begin assessing the drugs in proof-of-concept clinical trials in solid tumors and hematological malignancies.